Skip to main content

Haemophilus b conjugate (prp-omp) vaccine/hepatitis b pediatric vaccine Disease Interactions

There are 2 disease interactions with haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine.

Moderate

Hepatitis B vaccine (applies to haemophilus b conjugate (prp-omp) vaccine/hepatitis b pediatric vaccine) hemophilia

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Bleeding Associated with Coagulation Defect

Hepatitis B vaccine (adult and pediatric) is usually for intramuscular administration. However, it may be administered subcutaneously to persons at risk for hemorrhage following intramuscular injections (e.g., hemophiliacs), although it may result in lower antibody response. Additionally, when other aluminum- absorbed vaccines have been administered subcutaneously, an increased incidence of local reactions including subcutaneous nodules has been observed. Therefore, consider subcutaneous administration only in persons who are at risk of hemorrhage following intramuscular injections.

References

  1. "Product Information. Engerix-B Pediatric (HepB) (hepatitis B pediatric vaccine)." GlaxoSmithKline (2022):
  2. "Product Information. Recombivax HB Pediatric/Adolescent (hepatitis B pediatric vaccine)." Merck & Co., Inc (2022):
Moderate

Hepatitis B vaccine (applies to haemophilus b conjugate (prp-omp) vaccine/hepatitis b pediatric vaccine) low birth weight

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Prematurity/Underweight in Infancy

Hepatitis B vaccine should be deferred for infants with a birth weight less than 2,000 grams if the mother is documented to be HBsAg negative at the time of the infant's birth. If the mother is HBsAg positive (or the status cannot be determined), the infant should receive the vaccine within 12 hours after birth.
Apnea following intramuscular vaccination has been observed in some infants born prematurely and the decision to administer any intramuscular vaccine, including hepatitis B vaccine, should be based on consideration of the infant's medical status, and the potential benefits and risks of vaccination. Close monitoring is recommended.

References

  1. "Product Information. Engerix-B Pediatric (HepB) (hepatitis B pediatric vaccine)." GlaxoSmithKline (2022):
  2. "Product Information. Recombivax HB Pediatric/Adolescent (hepatitis B pediatric vaccine)." Merck & Co., Inc (2022):

Haemophilus b conjugate (prp-omp) vaccine/hepatitis b pediatric vaccine drug interactions

There are 288 drug interactions with haemophilus b conjugate (prp-omp) vaccine / hepatitis b pediatric vaccine.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.